Cardiovascular disease is a group of disorders related to the heart and blood vessels.
Building on Sanofi’s legacy of many years of fighting cardiovascular disease, we deliver therapeutic solutions for cardiovascular conditions to patients at high risk for cardiac events (such as a heart attack) and strive to enhance the quality of life for such patients.
Self-care can enhance wellbeing, prevent disease, curb illness and restore health. Self-care contributes significantly not only to better health, but more sustainable healthcare systems and will become increasingly important in the years to come.
In the UK, we have a 50-year heritage in this area. We leverage our strengths in science, together with our world-class pharmaceutical quality standards, to deliver consumer-driven, medicines and products across a number of key categories, including digestive health, pain care, allergy and vitamins and mineral supplements.
Diabetes is caused by either a lack of insulin in the body (type 1) or, in type 2 diabetes, either an inability of the body to produce enough insulin or of the body to use the insulin it produces.
At Sanofi, we have been developing insulin treatments for diabetes for close to a century. We build on our heritage and commitment to innovation, to improve quality of life and support patients and healthcare systems by offering more than medicines. By combining Sanofi’s quality drugs with services, we aim at giving new hope to thousands of people.
Immune disorders are diseases or conditions caused by a dysfunction of the immune system and include allergy, asthma and autoimmune diseases.
We are leading the science behind type 2 inflammation providing treatment options and a robust pipeline of potential new medicines for chronic immune disorders.
Sanofi is dedicated to bringing new options to patients with an unmet need and is working on developing innovative therapies to make a difference in the lives of people affected by immune disorders. Our immunology portfolio includes treatments for atopic dermatitis, severe asthma and rheumatoid arthritis.
Every season, influenza (or flu) does more damage than most people realise. It can affect your child or parent, a friend or family member, a colleague or loved one. Flu vaccination is one of the most effective interventions we have to reduce pressure on the health and social care system during the winter. And even though we have the power to protect against it, people are still needlessly suffering and dying.
Sanofi produces nearly 200 million doses of vaccines against seasonal influenza each year, which represents 40% of all influenza vaccines worldwide. We recognise, however, that more must be done to reduce the impact of influenza, hence we continue to research, develop solutions and work with the public health community that is stepping up to the fight.
Multiple Sclerosis (MS) is a chronic disease that affects each person differently, with symptoms ranging from numbness in the limbs or forgetfulness, to paralysis or loss of vision. MS is caused when the body’s immune system attacks the central nervous system, damaging the myelin sheath—the protective layer covering the nerves that carry signals between the brain and spinal cord and the rest of the body.
Sanofi has been working to develop novel treatments for Multiple Sclerosis for over ten years. With a current portfolio of products, Sanofi is committed to maintaining long-term partnerships with patients, physicians, advocates, and researchers to make a significant impact on people living with MS.
Sanofi recognises the incredible burden that cancer has on patients and those who care for them. Its relentless pursuit to advance scientific discovery is matched only by its determination to bring solutions to patients.
Sanofi is building on a rich legacy in oncology with a rejuvenated pipeline and a renewed commitment to bring novel treatment options to patients. Today, Sanofi has a portfolio of medicines across a variety of cancers, including skin, prostate, lung, colon, breast and blood.
Rare Blood Disorders
Sanofi has the opportunity to apply its legacy of a patient-centred approach with a commitment to innovation and rigorous clinical research to make a meaningful difference for people affected by rare blood disorders around the world.
Sanofi’s Rare Blood Disorders franchise is positioned for growth in this therapeutic area and has the potential to launch several prospective first-in-class therapies over the next five years, providing the opportunity to bring therapies to patients who currently have few options.
Patients with rare diseases can endure a long journey involving tests, misdiagnoses, and consulting specialty doctors. Focusing on these uncommon and underserved medical conditions, Sanofi’s rare disease franchise empowers the lives of patients with rare diseases with health care options that are highly specialised and can be transformative.
Built up over the years through in-house development and strategic acquisitions and partnerships, Sanofi’s Rare Disease franchise focuses on lysosomal storage disorders (LSDs) and other rare conditions such as Gaucher Disease.
By helping to keep travellers healthy and protecting them against infections found in other parts of the world such as Hepatitis A, Typhoid Fever, Rabies and Yellow-Fever, travel vaccines play a vital role in enabling people to achieve their full potential.
At Sanofi, we believe in a world in which a journey begins with knowledge and protection and ends with a safe and healthy return home
By helping to keep people healthy, vaccines play a vital role in preventing death and disability and enabling people to achieve their full potential.
For over 100 years, we have been committed to developing and manufacturing vaccines to help protect people around the world against a wide range of infectious diseases at every stage of life. We partner with the public health, medical and scientific communities to improve access to life-protecting vaccines and increase vaccination coverage, while striving to develop new and improved vaccines to enhance health and wellbeing.
At Sanofi, we believe that no one should ever suffer or die from a vaccine-preventable disease.
Job bag number MAT-GB-2002600(v3.0)
Last page update April 2022